Japan Cell Culture Media Market Size & Outlook, 2023-2030
Japan cell culture media market, 2018-2030 (US$M)
Related Markets
Japan cell culture media market highlights
- The Japan cell culture media market generated a revenue of USD 198.4 million in 2023 and is expected to reach USD 428.9 million by 2030.
- The Japan market is expected to grow at a CAGR of 11.6% from 2024 to 2030.
- In terms of segment, serum-free media was the largest revenue generating product in 2023.
- Serum-free Media is the most lucrative product segment registering the fastest growth during the forecast period.
Cell culture media market data book summary
| Market revenue in 2023 | USD 198.4 million |
| Market revenue in 2030 | USD 428.9 million |
| Growth rate | 11.6% (CAGR from 2023 to 2030) |
| Largest segment | Serum-free media |
| Fastest growing segment | Serum-free Media |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Serum-free Media, Classical Media, Stem Cell Culture Media, Chemically Defined Media, Specialty Media, Other Cell Culture Media |
| Key market players worldwide | Sartorius AG, Danaher Corp, Merck KGaA, Thermo Fisher Scientific Inc, FUJIFILM Holdings Corp, Lonza Group Ltd, BD, STEMCELL Technologies, PromoCell GmbH |
Other key industry trends
- In terms of revenue, Japan accounted for 4.2% of the global cell culture media market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China cell culture media market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 842.0 million by 2030.
Serum-free media was the largest segment with a revenue share of 34.78% in 2023. Horizon Databook has segmented the Japan cell culture media market based on serum-free media, classical media, stem cell culture media, chemically defined media, specialty media, other cell culture media covering the revenue growth of each sub-segment from 2018 to 2030.
There are two acts for regulation of regenerative medicines and cell therapy in Japan—The Act on the Safety of Regenerative Medicine (ASRM) and the Act on Pharmaceutical and Medical Devices (PMD Act). These two laws were enacted in November 2014. These laws fast track the process to the market for stem-cell-based treatments and other types of regenerative medicine.
The Act on the Safety of Regenerative Medicine allows operating players to register a therapy under one of three risk categories. Furthermore, it allows clinics and hospitals to commercialize cellular therapies without going through the usual kinds of trials to prove that a medicine is effective. It is mandatory for a hospital to have a cell processing facility certified by the Ministry of Health, Labor and Welfare to offer cellular therapies.
In addition, the Pharmaceutical and Medical Devices Act permits for conditional approval of therapies that have gone through some clinical testing. Companies are given the chance to promote a treatment across the country and get insurance payments; however, they are also required to gather additional efficacy data over a 7-year period.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell Culture Media Market Scope
Cell Culture Media Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Japan cell culture media market size, by product, 2018-2030 (US$M)
Japan Cell Culture Media Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
